肝细胞癌微环境中决定免疫治疗疗效的肿瘤免疫屏障的鉴定
该研究结合空间转录组学、单细胞RNA测序与多重免疫荧光,在接受抗PD-1治疗的肝细胞癌患者中鉴定出由SPP1+巨噬细胞与癌相关成纤维细胞在肿瘤边界附近构成的空间结构——肿瘤免疫屏障(TIB),其与免疫检查点阻断疗效相关;小鼠实验中阻断SPP1或巨噬细胞特异性敲除Spp1可增强抗PD-1疗效。
要点
- 肿瘤免疫屏障(TIB)是位于肿瘤边界附近、由SPP1+巨噬细胞与癌相关成纤维细胞构成的空间结构。
- TIB与肝细胞癌患者抗PD-1治疗疗效相关,其形成限制免疫细胞向肿瘤核心浸润。
- 小鼠中阻断SPP1或巨噬细胞特异性敲除Spp1可增强抗PD-1疗效,伴CAF浸润减少、细胞毒性T细胞浸润增加。
核心结论
- 由SPP1+巨噬细胞与癌相关成纤维细胞相互作用形成的肿瘤免疫屏障(TIB)结构与免疫治疗疗效相关。
- 作者认为,通过阻断SPP1破坏TIB结构可考虑作为增强肝细胞癌免疫检查点阻断疗效的相关治疗途径。
研究设计与样本
- 研究结合空间转录组学、单细胞RNA测序与多重免疫荧光,分析接受抗PD-1治疗的肝细胞癌患者的肿瘤微环境空间结构。
- 临床前采用小鼠肝癌模型,进行SPP1阻断或巨噬细胞特异性Spp1敲除联合抗PD-1治疗。
主要发现
- 鉴定出肿瘤免疫屏障(TIB),即位于肿瘤边界附近、由SPP1+巨噬细胞与癌相关成纤维细胞构成的空间生态位,与免疫检查点阻断疗效相关。
- 配体-受体网络分析显示,缺氧微环境促进SPP1表达,SPP1+巨噬细胞与CAF相互作用刺激细胞外基质重塑并促进TIB结构形成,从而限制肿瘤核心的免疫浸润。
- 小鼠中阻断SPP1或巨噬细胞特异性敲除Spp1可增强抗PD-1治疗疗效,伴CAF浸润减少与细胞毒性T细胞浸润增加。
临床怎么用
- 作者认为,通过阻断SPP1破坏TIB结构可考虑作为增强肝细胞癌免疫检查点阻断疗效的相关治疗途径。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: The tumour microenvironment (TME) is a crucial mediator of cancer progression and therapeutic outcome. The TME subtype correlates with patient response to immunotherapy in multiple cancers. Most previous studies have focused on the role of different cellular components in the TME associated with immunotherapy efficacy. However, the specific structure of the TME and its role in immunotherapy efficacy remain largely unknown. METHODS: We combined spatial transcriptomics with single-cell RNA-sequencing and multiplexed immunofluorescence to identify the specific spatial structures in the TME that determine the efficacy of immunotherapy in patients with hepatocellular carcinoma (HCC) receiving anti-PD-1 treatment. RESULTS: We identified a tumour immune barrier (TIB) structure, a spatial niche composed of SPP1+ macrophages and cancer-associated fibroblasts (CAFs) located near the tumour boundary, which is associated with the efficacy of immune checkpoint blockade. Furthermore, we dissected ligand‒receptor networks among malignant cells, SPP1+ macrophages, and CAFs; that is, the hypoxic microenvironment promotes SPP1 expression, and SPP1+ macrophages interact with CAFs to stimulate extracellular matrix remodelling and promote TIB structure formation, thereby limiting immune infiltration in the tumour core. Preclinically, the blockade of SPP1 or macrophage-specific deletion of Spp1 in mice led to enhanced efficacy of anti-PD-1 treatment in mouse liver cancer, accompanied by reduced CAF infiltration and increased cytotoxic T-cell infiltration. CONCLUSIONS: We identified that the TIB structure formed by the interaction of SPP1+ macrophages and CAFs is related to immunotherapy efficacy. Therefore, disruption of the TIB structure by blocking SPP1 may be considered a relevant therapeutic approach to enhance the therapeutic effect of immune checkpoint blockade in HCC. IMPACT AND IMPLICATIONS: Only a limited number of patients with hepatocellular carcinoma (HCC) benefit from tumour immunotherapy, which significantly hinders its application. Herein, we used multiomics to identify the spatial structure of the tumour immune barrier (TIB), which is formed by the interaction of SPP1+ macrophages and cancer-associated fibroblasts in the HCC microenvironment. This structure constrains immunotherapy efficacy by limiting immune cell infiltration into malignant regions. Preclinically, we revealed that blocking SPP1 or macrophage-specific deletion of Spp1 in mice could destroy the TIB structure and sensitize HCC cells to immunotherapy. These results provide the first key steps towards finding more effective therapies for HCC and have implications for physicians, scientists, and drug developers in the field of HCC.
引用
- Liu Y, Xun Z, Ma K, et al. Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy. J Hepatol. 2023. PMID: 36708811. doi:10.1016/j.jhep.2023.01.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。